13-Year-Old Boy Becomes First to Be Cured of Terminal Brain Tumor


In an unprecedented medical breakthrough, a 13-year-old boy named Lucas has been cured of a deadly brain tumor known as diffuse intrinsic pontine glioma (DIPG).

This rare and aggressive cancer typically leaves patients with a survival time of only nine to ten months.

Lucas’s recovery offers new hope for more effective treatments.

Understanding DIPG

DIPG is a rare form of cancer that primarily affects children, with about 300 cases diagnosed each year in the United States.

This tumor is located in the brainstem, which controls many vital functions, making surgical removal impossible.

Because of its aggressive nature and inoperable location, DIPG has been one of the most challenging cancers to treat.

Lucas’s Battle with DIPG

Lucas, a young boy from Belgium, was diagnosed with DIPG at the age of six.

Seeking the best possible care, his parents took him to France, where he was enrolled in the Biological Medicine for DIPG Eradication (BIOMEDE) study.

This study began in 2014 and aimed to find more effective treatments for DIPG by testing three different cancer drugs: erlotinib, everolimus, and dasatinib.

Personalized Treatment Approach

A key aspect of the BIOMEDE study was the personalized treatment approach.

Researchers first extracted a tiny fragment of each patient’s tumor through a biopsy to analyze its molecular profile.

This detailed analysis allowed doctors to tailor the treatment to the specific characteristics of each patient’s cancer.

Lucas’s tumor analysis indicated that everolimus was the most suitable drug for his condition.

Remarkable Recovery

Under the care of Dr. Jacques Grill, the lead researcher of BIOMEDE, Lucas began his treatment with everolimus.

Over the course of his therapy, repeated MRI scans showed that his tumor was shrinking.

Remarkably, by the age of 13, Lucas’s tumor had completely disappeared.

Dr. Grill expressed his amazement, stating, “Over a series of MRI scans, I watched as the tumor completely disappeared.”

Lucas is now cancer-free, a result that no other DIPG patient in the world has achieved.

Why Did Lucas Respond So Well?

Researchers are trying to understand why Lucas responded so uniquely to the treatment.

Dr. Grill noted that Lucas’s tumor had an extremely rare mutation, which they believe made it more sensitive to everolimus.

This insight could be crucial in developing more effective treatments for other DIPG patients.

Future Research and Challenges

The success of the initial BIOMEDE study, which ran until 2019, led researchers to choose everolimus for the BIOMEDE 2.0 study, which began in September 2022.

The ongoing research aims to deepen the understanding of DIPG and improve treatment strategies.

Scientists are also working on creating cancer organoids—bundles of lab-grown cells that mimic the genetic abnormalities of patients’ tumors.

These organoids could be used to test new drugs and treatment methods more effectively.

However, developing new treatments is a lengthy and complex process.

Dr. Grill cautioned that it typically takes 10-15 years from the initial discovery of a potential treatment to its widespread use.

Despite the long road ahead, Lucas’s story offers hope and highlights the potential of personalized medicine in treating aggressive cancers like DIPG.


Lucas’s cure represents a significant milestone in cancer research, providing a beacon of hope for many families affected by DIPG.

The insights gained from his treatment could pave the way for new, more effective therapies and bring us closer to overcoming this devastating disease.